Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Transfusion independence after repeated haploidentical hematopoietic cell transplants in a patient with congenital dyserythropoietic anemia type II and hemosiderosis.

Macaraeg M, Proytcheva M, Katsanis E.

Pediatr Transplant. 2019 Dec;23(8):e13587. doi: 10.1111/petr.13587. Epub 2019 Sep 17.

PMID:
31529567
2.

The Impact of Low-Dose Cranial Boost on the Long-Term Outcomes of Adult Patients with High-Risk Acute Lymphoblastic Leukemia Undergoing Total Body Irradiation and Allogeneic Hematopoietic Stem Cell Transplantation.

Famoso JM, Grow JL, Laughlin B, Katsanis E, Stea B.

Pract Radiat Oncol. 2019 May;9(3):e283-e289. doi: 10.1016/j.prro.2018.12.005. Epub 2018 Dec 20.

PMID:
30578956
3.

Esophageal Varices in Adolescent and Young Adult Males with Acute Lymphocytic Leukemia.

Nicholls L, Montez J, Pelayo-Katsanis L, Katsanis E.

J Adolesc Young Adult Oncol. 2019 Apr;8(2):217-220. doi: 10.1089/jayao.2018.0098. Epub 2018 Oct 18.

PMID:
30335538
4.

Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells.

Stokes J, Hoffman EA, Molina MS, Eremija J, Larmonier N, Zeng Y, Katsanis E.

Biol Blood Marrow Transplant. 2019 Mar;25(3):405-416. doi: 10.1016/j.bbmt.2018.10.009. Epub 2018 Oct 13.

PMID:
30326280
5.

Supernumerary Incisors in CB6F1 Mice Conditioned with Chemotherapy and Total Body Irradiation before Bone Marrow Transplantation.

Doane CJ, Patil K, Hoffman EA, Stokes J, Katsanis E, Besselsen DG.

Comp Med. 2018 Oct 1;68(5):349-352. doi: 10.30802/AALAS-CM-18-000043. Epub 2018 Sep 12.

6.

β2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans.

Graff RM, Kunz HE, Agha NH, Baker FL, Laughlin M, Bigley AB, Markofski MM, LaVoy EC, Katsanis E, Bond RA, Bollard CM, Simpson RJ.

Brain Behav Immun. 2018 Nov;74:143-153. doi: 10.1016/j.bbi.2018.08.017. Epub 2018 Aug 30.

PMID:
30172948
7.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.

Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2034-2039. doi: 10.1016/j.bbmt.2018.06.007. Epub 2018 Jun 14.

8.

Successful resolution of hyperammonemia following hematopoietic cell transplantation with directed treatment of Ureaplasma parvum infection.

Graetz R, Meyer R, Shehab K, Katsanis E.

Transpl Infect Dis. 2018 Apr;20(2):e12839. doi: 10.1111/tid.12839. Epub 2018 Feb 12.

PMID:
29359847
9.

Pak2 regulates myeloid-derived suppressor cell development in mice.

Zeng Y, Hahn S, Stokes J, Hoffman EA, Schmelz M, Proytcheva M, Chernoff J, Katsanis E.

Blood Adv. 2017 Oct 10;1(22):1923-1933. doi: 10.1182/bloodadvances.2017007435. eCollection 2017 Oct 10.

10.

Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation.

Zeng Y, Katsanis E.

Bone Marrow Transplant. 2017 Dec;52(12):1671-1673. doi: 10.1038/bmt.2017.186. Epub 2017 Sep 18. No abstract available.

PMID:
28920946
11.

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.

Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M.

Br J Haematol. 2018 Sep;182(6):916-920. doi: 10.1111/bjh.14879. Epub 2017 Aug 2. No abstract available.

12.

Allogeneic Transplant in ELANE and MEFV Mutation Positive Severe Cyclic Neutropenia: Review of Prognostic Factors for Secondary Severe Events.

Okolo ON, Katsanis E, Yun S, Reveles CY, Anwer F.

Case Rep Hematol. 2017;2017:5375793. doi: 10.1155/2017/5375793. Epub 2017 Jan 18.

13.
14.

Targeted immunotherapy for pediatric solid tumors.

Kopp LM, Katsanis E.

Oncoimmunology. 2015 Aug 31;5(3):e1087637. eCollection 2016 Mar. Review.

15.

Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.

Stokes J, Hoffman EA, Zeng Y, Larmonier N, Katsanis E.

Br J Haematol. 2016 Jul;174(1):102-16. doi: 10.1111/bjh.14034. Epub 2016 Mar 31.

16.

Extramedullary Breast Relapse of Acute Lymphoblastic Leukemia Controlled with a Second Allogeneic/Autologous Hematopoietic Cell Transplant.

Houghtelin AB, Kopp LM, Pelayo-Katsanis L, Kuo PH, Yeager AM, Katsanis E.

J Adolesc Young Adult Oncol. 2015 Mar;4(1):50-3. doi: 10.1089/jayao.2014.0018. Epub 2015 Mar 3.

PMID:
26812431
17.

Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia.

Menon NN, Jenkins LM, Cui H, Jenkins C, Anwer F, Yeager AM, Katsanis E.

Ann Hematol. 2016 Mar;95(4):637-44. doi: 10.1007/s00277-016-2599-9. Epub 2016 Jan 20.

PMID:
26787415
18.

T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1.

Trad M, Gautheron A, Fraszczak J, Alizadeh D, Larmonier C, LaCasse CJ, Centuori S, Audia S, Samson M, Ciudad M, Bonnefoy F, Lemaire-Ewing S, Katsanis E, Perruche S, Saas P, Bonnotte B.

Biomed Res Int. 2015;2015:891236. doi: 10.1155/2015/891236. Epub 2015 Sep 30.

19.

The complex pathophysiology of acquired aplastic anaemia.

Zeng Y, Katsanis E.

Clin Exp Immunol. 2015 Jun;180(3):361-70. doi: 10.1111/cei.12605. Epub 2015 Apr 23. Review.

20.

Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines.

Graner MW, Lillehei KO, Katsanis E.

Front Oncol. 2015 Jan 6;4:379. doi: 10.3389/fonc.2014.00379. eCollection 2014. Review.

21.

Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracycline-induced cardiomyopathy.

Menon NM, Katsanis E, Khalpey Z, Whitlow P.

Pediatr Blood Cancer. 2015 Jan;62(1):166-8. doi: 10.1002/pbc.25204. Epub 2014 Aug 31.

PMID:
25175922
22.

Outcomes after hematopoietic stem cell transplantation for children with I-cell disease.

Lund TC, Cathey SS, Miller WP, Eapen M, Andreansky M, Dvorak CC, Davis JH, Dalal JD, Devine SM, Eames GM, Ferguson WS, Giller RH, He W, Kurtzberg J, Krance R, Katsanis E, Lewis VA, Sahdev I, Orchard PJ.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1847-51. doi: 10.1016/j.bbmt.2014.06.019. Epub 2014 Jul 10.

23.

PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.

Hanke NT, LaCasse CJ, Larmonier CB, Alizadeh D, Trad M, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Eur J Immunol. 2014 Aug;44(8):2489-2499. doi: 10.1002/eji.201343803. Epub 2014 May 23.

24.

Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD.

Zeng Y, Stokes J, Hahn S, Hoffman E, Katsanis E.

Bone Marrow Transplant. 2014 Aug;49(8):1076-83. doi: 10.1038/bmt.2014.91. Epub 2014 Apr 28.

PMID:
24777185
25.

Chemotherapeutic targeting of myeloid-derived suppressor cells.

Alizadeh D, Katsanis E, Larmonier N.

Oncoimmunology. 2014 Jan 1;3(1):e27359.

26.

Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue: the pediatric blood and marrow transplant consortium experience and review of the literature.

Karski EE, Dvorak CC, Leung W, Miller W, Shaw PJ, Qayed M, Katsanis E, Feusner JH.

J Pediatr Hematol Oncol. 2014 Jul;36(5):362-8. doi: 10.1097/MPH.0000000000000130. Review.

PMID:
24577552
27.

The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer.

Alizadeh D, Katsanis E, Larmonier N.

Clin Dev Immunol. 2013;2013:957878. doi: 10.1155/2013/957878. Epub 2013 Dec 28. Review.

28.

Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.

Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Cancer Res. 2014 Jan 1;74(1):104-18. doi: 10.1158/0008-5472.CAN-13-1545. Epub 2013 Nov 6.

29.

Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine.

Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Har-Noy M, Lillehei KO, Katsanis E, Graner MW.

Int J Hyperthermia. 2013 Aug;29(5):390-8. doi: 10.3109/02656736.2013.800997. Epub 2013 Jun 20.

PMID:
23786302
30.

The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity.

Graner MW, Romanoski A, Katsanis E.

Int J Hyperthermia. 2013 Aug;29(5):380-9. doi: 10.3109/02656736.2013.793406. Epub 2013 May 31.

PMID:
23725202
31.

Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.

Hanke N, Alizadeh D, Katsanis E, Larmonier N.

Crit Rev Immunol. 2013;33(1):1-21. Review.

32.

Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells.

Centuori SM, Trad M, LaCasse CJ, Alizadeh D, Larmonier CB, Hanke NT, Kartchner J, Janikashvili N, Bonnotte B, Larmonier N, Katsanis E.

J Leukoc Biol. 2012 Nov;92(5):987-97. doi: 10.1189/jlb.0911465. Epub 2012 Aug 13.

33.

Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells.

Larmonier N, Bonnotte B, Katsanis E.

Oncoimmunology. 2012 Jul 1;1(4):566-568.

34.

Late effects in adult survivors of pediatric cancer: a guide for the primary care physician.

Kopp LM, Gupta P, Pelayo-Katsanis L, Wittman B, Katsanis E.

Am J Med. 2012 Jul;125(7):636-41. doi: 10.1016/j.amjmed.2012.01.013. Epub 2012 May 4. Review.

PMID:
22560808
35.

Diagnostic and treatment challenges for the pediatric hematologist oncologist in endemic areas for coccidioidomycosis.

Bravo R, Pelayo-Katsanis LO, Shehab ZM, Katsanis E.

J Pediatr Hematol Oncol. 2012 Jul;34(5):389-94. doi: 10.1097/MPH.0b013e3182496658.

PMID:
22510771
36.

The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance.

Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.

Clin Dev Immunol. 2011;2011:430394. doi: 10.1155/2011/430394. Epub 2011 Nov 3. Review.

37.

Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.

LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M, Bonnotte B, Katsanis E, Larmonier N.

J Immunol. 2011 Dec 15;187(12):6310-7. doi: 10.4049/jimmunol.1101812. Epub 2011 Nov 9.

38.

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.

Audia S, Samson M, Guy J, Janikashvili N, Fraszczak J, Trad M, Ciudad M, Leguy V, Berthier S, Petrella T, Aho-Glélé S, Martin L, Maynadié M, Lorcerie B, Rat P, Cheynel N, Katsanis E, Larmonier N, Bonnotte B.

Blood. 2011 Oct 20;118(16):4394-400. doi: 10.1182/blood-2011-03-344051. Epub 2011 Aug 29.

39.

Cytotoxic dendritic cells generated from cancer patients.

Lakomy D, Janikashvili N, Fraszczak J, Trad M, Audia S, Samson M, Ciudad M, Vinit J, Vergely C, Caillot D, Foucher P, Lagrost L, Chouaib S, Katsanis E, Larmonier N, Bonnotte B.

J Immunol. 2011 Sep 1;187(5):2775-82. doi: 10.4049/jimmunol.1004146. Epub 2011 Jul 29.

40.

Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.

Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E.

Blood. 2011 Feb 3;117(5):1555-64. doi: 10.1182/blood-2010-06-288621. Epub 2010 Dec 1.

41.

Personalized dendritic cell-based tumor immunotherapy.

Janikashvili N, Larmonier N, Katsanis E.

Immunotherapy. 2010 Jan;2(1):57-68. Review.

42.

Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells.

Fraszczak J, Trad M, Janikashvili N, Cathelin D, Lakomy D, Granci V, Morizot A, Audia S, Micheau O, Lagrost L, Katsanis E, Solary E, Larmonier N, Bonnotte B.

J Immunol. 2010 Feb 15;184(4):1876-84. doi: 10.4049/jimmunol.0900831. Epub 2010 Jan 20.

43.

Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells.

Cantrell J, Larmonier C, Janikashvili N, Bustamante S, Fraszczak J, Herrell A, Lundeen T, J LaCasse C, Situ E, Larmonier N, Katsanis E.

Immunobiology. 2010 Jul;215(7):535-44. doi: 10.1016/j.imbio.2009.09.006. Epub 2009 Oct 31.

44.

Killer dendritic cells and their potential for cancer immunotherapy.

Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E.

Cancer Immunol Immunother. 2010 Jan;59(1):1-11. doi: 10.1007/s00262-009-0736-1. Epub 2009 Jul 18. Review.

PMID:
19618185
45.

Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.

Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, Lundeen T, Bonnotte B, Katsanis E.

J Immunol. 2008 Nov 15;181(10):6955-63.

46.

Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.

Bleifuss E, Bendz H, Sirch B, Thompson S, Brandl A, Milani V, Graner MW, Drexler I, Kuppner M, Katsanis E, Noessner E, Issels RD.

Int J Hyperthermia. 2008 Dec;24(8):623-37. doi: 10.1080/02656730802213384.

PMID:
18608582
47.

A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.

Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet ML, Katsanis E.

Mol Cancer Ther. 2008 Mar;7(3):721-9. doi: 10.1158/1535-7163.MCT-07-2067.

48.

Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression.

Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, Sepassi M, Andreansky S, Katsanis E.

J Leukoc Biol. 2008 Apr;83(4):1049-59. doi: 10.1189/jlb.0907635. Epub 2008 Jan 3.

PMID:
18174364
49.

The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model.

Larmonier N, Cathelin D, Larmonier C, Nicolas A, Merino D, Janikashvili N, Audia S, Bateman A, Thompson J, Kottke T, Hartung T, Katsanis E, Vile R, Bonnotte B.

Exp Cell Res. 2007 Jul 1;313(11):2345-55. Epub 2007 Mar 30.

PMID:
17466973
50.

Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro.

Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, Andreansky S, Brewer MA, Katsanis E.

Clin Exp Immunol. 2007 Apr;148(1):136-45.

Supplemental Content

Loading ...
Support Center